2025 Europe Cancer Gene Therapy Market Revenue Opportunities Report
Description
The 2025 Europe Cancer Gene Therapy Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Gene Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cancer Gene Therapy Market in Europe include Novartis, Gilead Sciences, Amgen, and Orchard Therapeutics. Novartis leads with a strong presence in gene and cell therapy, backed by extensive investments in research and numerous product approvals in Europe, especially Germany, which holds the largest regional market share. Gilead Sciences and Amgen also play significant roles through their advanced gene therapy pipelines and collaborations within European oncology markets. Orchard Therapeutics specializes in rare genetic disorders but also extends into oncology gene therapies, supported by robust clinical trial activities and regulatory advancements in Europe.
In addition, companies like Adaptimmune Therapeutics (UK) and BioNTech SE (Germany) complement these key players by focusing on innovative T-cell therapies and bispecific antibodies targeting cancer. The European market is expected to grow strongly with a CAGR exceeding 18%, driven by increasing investments, favorable regulatory frameworks, and a rise in oncolytic virotherapy products. Germany and the UK serve as prominent hubs for cancer gene therapy research and commercialization, facilitating the advancement of these companies’ technologies across Europe.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Cancer Gene Therapy Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the Cancer Gene Therapy Market in Europe include Novartis, Gilead Sciences, Amgen, and Orchard Therapeutics. Novartis leads with a strong presence in gene and cell therapy, backed by extensive investments in research and numerous product approvals in Europe, especially Germany, which holds the largest regional market share. Gilead Sciences and Amgen also play significant roles through their advanced gene therapy pipelines and collaborations within European oncology markets. Orchard Therapeutics specializes in rare genetic disorders but also extends into oncology gene therapies, supported by robust clinical trial activities and regulatory advancements in Europe.
In addition, companies like Adaptimmune Therapeutics (UK) and BioNTech SE (Germany) complement these key players by focusing on innovative T-cell therapies and bispecific antibodies targeting cancer. The European market is expected to grow strongly with a CAGR exceeding 18%, driven by increasing investments, favorable regulatory frameworks, and a rise in oncolytic virotherapy products. Germany and the UK serve as prominent hubs for cancer gene therapy research and commercialization, facilitating the advancement of these companies’ technologies across Europe.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
